Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation

Chih-Hsien Cheng; Hao-Chien Hung; Jin-Chiao Lee; Yu-Chao Wang; Tsung-Han Wu; Chen-Fang Lee; Ting-Jung Wu; Hong-Shiue Chou; Kun-Ming Chan; Wei-Chen Lee

doi:10.12659/AOT.938731

21 April 2023 : Original article

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation

Chih-Hsien Cheng^1ABCDE*, Hao-Chien Hung^1BC, Jin-Chiao Lee^1BC, Yu-Chao Wang^1CD, Tsung-Han Wu^1CD, Chen-Fang Lee^1ABC, Ting-Jung Wu^1BC, Hong-Shiue Chou^1BC, Kun-Ming Chan

^1BC, Wei-Chen Lee^1ABCD

DOI: 10.12659/AOT.938731

Ann Transplant 2023; 28:e938731

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 3 Renal function change during therapy with TDF and TAFMedian (IQR) eGFR percentage change from baseline at weeks 24 and 48 during TDF and TAF treatment. n.s. not significant, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 (Wilcoxon paired test).

Back to the Article

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation

Your Privacy